Redeye sees a solid Q2 report from Fortnox, with basically every line beating our forecasts slightly...
Redeye comments on Carasent's Q2 2023 report, which showed small improvements compared to the previo...
Redeye retains its positive view of Formpipe following a solid Q2, largely matching our forecasts.
Redeye provides its initial take on Vitec’s Q2 2023 report, which came in broadly above our estimate...
Consumables did not make up for a softer period in Genomic Services and Technologies.
Redeye’s first comments following this morning’s Q2 report from Tagmaster.
Redeye raises its base case for BONESUPORT following the Q2 2023 report, where our US CERAMENT G sal...
Redeye states that Doro’s Q2 2023 report was inline with Redeyes expectation on topline but higher O...
Redeye updates our outlook after Q2. XVIVO’s result indicated a mix of organisational improvements a...
Redeye is convinced by the second interim readout of mitazalimab in which the objective response rat...
Redeye saw a sales performance that was very weak and thus did not meet our expectations.
Redeye provides a preview ahead of Embracer Group’s Q1 2023/24e report, due on 17 August.
Redeye comments on AVTECH's preliminary figures, which were in line with our estimates.
Q2-rapporten bjuder på ökade hyresintäkter men stigande ränta pressar förvaltningsresultatet.
-9% organisk tillväxt… Med 5-6% negativ påverkan från pris (fallande fraktpriser), vilket kommer for...
Fastighetsverksamheten visar styrka trots stigande räntor.
Bolaget levererar på uppföljningsmålet och Fas 2b-studien med STA363 löper enligt plan.
Redeye återkommer med en update efter BioArctics Q2-rapport och det nyliga fullständiga godkännandet...
Redeye comments on the topline result of the phase I trial of Lipisense, which demonstrated a favour...
Redeye sees a Q2 report that was surprisingly weak, with a negative sales development in the quarter...
